Share

May 15, 2012; 78 (20) Articles

Patterns of treatment response in newly diagnosed epilepsy

M.J. Brodie, S.J.E. Barry, G.A. Bamagous, J.D. Norrie, P. Kwan
First published May 9, 2012, DOI: https://doi.org/10.1212/WNL.0b013e3182563b19
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
3881

Share

Article Information

vol. 78 no. 20 1548-1554
DOI: 
https://doi.org/10.1212/WNL.0b013e3182563b19
PubMed: 
22573629
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received June 8, 2011
  • Accepted October 26, 2011
  • First Published May 9, 2012.

Article Versions

Copyright & Usage: 
Copyright © 2012 by AAN Enterprises, Inc.

Author Disclosures

    1. M.J. Brodie, MD,
    2. S.J.E. Barry, PhD,
    3. G.A. Bamagous, PhD,
    4. J.D. Norrie, MSc and
    5. P. Kwan, MD, PhD
  1. M.J. Brodie, MD,
    2. Scientific Advisory Boards:

    1. Pfizer Inc; UCB; Eisai Inc; GlaxoSmithKline; Novartis; Sanofi Aventis; Upsher-Smith; Lundbeck Inc

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. UCB, speaker honoraria and travel to and from meetings; GlaxoSmithKline, speaker honoraria; Eisai Inc, speaker honoraria

    Editorial Boards:

    1. Seizure, Editorial Board, 2000 to date; Epilepsy & Behavior, Editoral Board, 2005 to date; CNS Drugs, Editorial Board, 2009 to date; Acta Neurologica Scandinavia, Editorial Board, 2010 to date

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Eisai Inc Speakers’ Bureaus:; UCB; GlaxoSmithKline; Eisai Inc

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Eisai Inc; GlaxoSmithKline

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. S.J.E. Barry, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. G.A. Bamagous, PhD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. J.D. Norrie, MSc and
    5. Scientific Advisory Boards:

    1. I have served as independent statistician and/or chair on 7 publicly funded iDMC during the last 2 years.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. I am co grant holder on a number of UK NIHR/HTA and UK NIHR/MRC grants, likewise Scottish Government CSO grants.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. P. Kwan, MD, PhD
    6. Scientific Advisory Boards:

    1. Pfizer Inc, scientific advisory board

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Sanofi, speaker honorarium

    Editorial Boards:

    1. Editorial Boards:; Epilepsy and Behavior; Seizure; Epileptic Disorders; CNS Drugs

    Patents:

    1. Application filed to patent on a rapid HLA typing method (PCT/CN2009/074891)

    Publishing Royalties:

    1. Fast Facts: Epilepsy. By Health Press, Oxford, UK

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. UCB

    Speakers’ Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Eisai; Johnson & Johnson; Pfizer; UCB

    Research Support, Government Entities:

    1. NINDS/Forgarty International Center (1R21NS069223), contact PI, 2000-2012

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Epilepsy Unit (M.J.B., G.A.B.), Western Infirmary, Glasgow; Robertson Centre for Biostatistics (S.J.E.B.), University of Glasgow, Glasgow; Centre for Healthcare Randomised Trials (J.D.N.), Health Services Research Unit, University of Aberdeen, Aberdeen, Scotland, UK; Departments of Medicine and Neurology (P.K.), The University of Melbourne, Royal Melbourne Hospital, Melbourne, Australia; and Department of Medicine and Therapeutics (P.K.), The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong.
  1. Correspondence & reprint requests to Dr. Kwan: patrick.kwan{at}unimelb.edu.au
View Full Text

Article usage

Article usage: May 2012 to April 2023

AbstractFullPdfSource
May 2012233487218Highwire
Jun 2012372229198Highwire
Jul 20122143667Highwire
Aug 20121461934Highwire
Sep 20121382033Highwire
Oct 2012892332Highwire
Nov 20121301634Highwire
Dec 201267513Highwire
Jan 2013771013Highwire
Feb 2013791310Highwire
Mar 201394814Highwire
Apr 20131101017Highwire
May 2013108317Highwire
Jun 20135367Highwire
Jul 20135378Highwire
Aug 20134334Highwire
Sep 2013731415Highwire
Oct 20131011220Highwire
Nov 2013661214Highwire
Dec 201346711Highwire
Jan 201451910Highwire
Jan 2014037271pmc
Feb 201449813Highwire
Mar 201473911Highwire
Apr 201465613Highwire
May 201455610Highwire
Jun 201436713Highwire
Jul 201468410Highwire
Aug 201470912Highwire
Sep 2014841215Highwire
Oct 201486711Highwire
Nov 20147877Highwire
Dec 201475117Highwire
Jan 201584355Highwire
Jan 201504739pmc
Feb 20156584Highwire
Feb 201505339pmc
Mar 2015110118Highwire
Mar 201509453pmc
Apr 20159143Highwire
Apr 201506858pmc
May 20158398Highwire
May 201505935pmc
Jun 2015901215Highwire
Jun 201504325pmc
Jul 20159235Highwire
Jul 201504223pmc
Aug 201595209Highwire
Aug 201506033pmc
Sep 20151053316Highwire
Sep 201504736pmc
Oct 201599445Highwire
Oct 201507243pmc
Nov 201598147Highwire
Nov 201509333pmc
Dec 20156998Highwire
Dec 201505234pmc
Jan 20161491411Highwire
Jan 201607050pmc
Feb 201671105Highwire
Feb 201605288pmc
Mar 2016751210Highwire
Mar 201606843pmc
Apr 201662107Highwire
Apr 201606633pmc
May 20165987Highwire
May 201605127pmc
Jun 20164413Highwire
Jun 201604438pmc
Jul 20166178Highwire
Jul 201604735pmc
Aug 20166946Highwire
Aug 201607541pmc
Sep 20168797Highwire
Sep 201607234pmc
Oct 20169645Highwire
Oct 201609747pmc
Nov 201615537Highwire
Nov 201608956pmc
Dec 20165995Highwire
Dec 201608247pmc
Jan 20176135Highwire
Jan 201708255pmc
Feb 20177324Highwire
Feb 201708533pmc
Mar 2017691210Highwire
Mar 201706533pmc
Apr 201710845Highwire
Apr 2017317597pmc
May 20176556Highwire
May 2017416379pmc
Jun 20176345Highwire
Jun 2017416979pmc
Jul 20173477Highwire
Jul 2017426878pmc
Aug 20175269Highwire
Aug 2017276978pmc
Sep 20175547Highwire
Sep 2017508495pmc
Oct 20175448Highwire
Oct 20173893104pmc
Nov 20176979Highwire
Nov 201752101107pmc
Dec 201752332Highwire
Jan 2018518115Highwire
Feb 2018607237Highwire
Mar 2018665169Highwire
Apr 2018602139Highwire
Apr 2018326672pmc
May 201859589Highwire
Jun 2018409155Highwire
Jun 2018306570pmc
Jul 2018706128Highwire
Aug 201877164Highwire
Aug 2018369084pmc
Sep 201868569Highwire
Oct 201865247Highwire
Nov 20186191110Highwire
Dec 201883395Highwire
Jan 2019855613Highwire
Feb 201974145Highwire
Mar 201974617Highwire
Apr 201970995Highwire
May 2019849105Highwire
Jun 2019734127Highwire
Jul 2019849912Highwire
Aug 201979988Highwire
Sep 201977488Highwire
Oct 2019853610Highwire
Nov 2019798511Highwire
Dec 201985039Highwire
Jan 2020822717Highwire
Feb 202081246Highwire
Mar 202067946Highwire
Apr 202077223Highwire
May 202089722Highwire
Jun 2020808104Highwire
Jul 202080814Highwire
Aug 202077375Highwire
Sep 2020849118Highwire
Oct 202062634Highwire
Nov 202077983Highwire
Dec 202081810Highwire
Jan 2021743133Highwire
Feb 2021574104Highwire
Mar 2021913116Highwire
Apr 202183931Highwire
May 2021862113Highwire
Jun 202185554Highwire
Jul 202185374Highwire
Aug 20219091510Highwire
Sep 202184386Highwire
Oct 202187255Highwire
Nov 202187422Highwire
Dec 202185532Highwire
Jan 202286834Highwire
Feb 202280158Highwire
Mar 202290267Highwire
Apr 202291088Highwire
May 2022985127Highwire
Jun 202265572Highwire
Jul 202290125Highwire
Aug 2022920109Highwire
Sep 202291677Highwire
Oct 2022898119Highwire
Nov 2022821147Highwire
Dec 202282678Highwire
Jan 202396266Highwire
Feb 202384352Highwire
Mar 202386054Highwire
Apr 202382622Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me

Recommended articles